ETOPOSIDE

Relapse/Recurrence

Zhejiang Cancer HospitalSmall moleculePhase 2Dormant

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 81/ 100

Competitive context

7 Active assets in the Relapse/Recurrence cohort.

Asset / Sponsor	Phase	Rating
cd19-ucart Beijing Boren Hospital	Phase 2	B
Venetoclax Shenzhen University General Hospital	Phase 2	CCC
Azacitidine Children's Hospital of Soochow University	Phase 2	CCC
Ifosfamide Zhejiang Cancer Hospital	Phase 2	CCC
Tirelizumab Zhejiang Cancer Hospital	Phase 2	CCC

View all 10 →

Same molecule, other indications

ETOPOSIDE is also rated in:

acute megakaryoblastic leukemiaDormant

BBB

Indicative ·

79 / 100

acute monocytic leukemiaDormant

BBB

Indicative ·

79 / 100

acute myeloblastic leukemia with maturationDormant

BBB

Indicative ·

79 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.